Purpose: Poloxamer 407 (P407) thermo-sensitive hydrogel formulations were developed to enhance the retention time in the urinary bladder after intravesical instillation. Materials and Methods: P407 hydrogels (P407Gels) containing 0.2 w/w% fluorescein isothiocyanate dextran (FD, MW 4 kDa) as a fluorescent probe were prepared by the cold method with different concentrations of the polymer (20, 25, and 30 w/w%). The gel-forming capacities were characterized in terms of gelation temperature (G-Temp), gelation time (G-Time), and gel duration (G-Dur). Homogenous dispersion of the probe throughout the hydrogel was observed by using fluorescence microscopy. The in vitro bladder simulation model was established to evaluate the retention and drug release properties. P407Gels in the solution state were administered to nude mice via urinary instillation, and the in vivo retention behavior of P407Gels was visualized by using an in vivo imaging system (IVIS). Results: P407Gels showed a thermo-reversible phase transition at 4°C (refrigerated; sol) and 37°C (body temperature; gel). The G-Temp, G-Time, and G-Dur of FD-free P407Gels were approximately 10°C-20°C, 12-30 seconds, and 12-35 hours, respectively, and were not altered by the addition of FD. Fluorescence imaging showed that FD was spread homogenously in the gelled P407 solution. In a bladder simulation model, even after repeated periodic filling-emptying cycles, the hydrogel formulation displayed excellent retention with continuous release of the probe over 8 hours. The FD release from P407Gels and the erosion of the gel, both of which followed zero-order kinetics, had a linear relationship (r 2 =0.988). IVIS demonstrated that the intravesical retention time of P407Gels was over 4 hours, which was longer than that of the FD solution (＜1 hour), even though periodic urination occurred in the mice. Conclusions: FD release from P407Gels was erosion-controlled. P407Gels represent a promising system to enhance intravesical retention with extended drug delivery. (Korean J Urol Oncol 2017;15:178-186) Key Words: Poloxamer 407ㆍIntravesical deliveryㆍThermo-sensitive hydrogelㆍBladder simulation modelㆍIn vivo imaging system
INTRODUCTION
Many drugs are used for the treatment of bladder diseases.
As they are predominantly administered via the oral route, only a small fraction of the administered drug reaches the bladder.
In such cases, the concentration of the drug in the bladder tissue fails to reach the therapeutic range; to overcome this obstacle, the dose must be increased, which leads to an increased level of side effects. 1, 2 An alternative, intravesical drug delivery (IDD), involves direct administration of the therapeutic drug into the bladder cavity through catheterization, achieving more concentrated drug exposure and reduced systemic effects.
However, there are limitations to IDD: first, the instilled drug is gradually diluted by urine and washed out during periodical urination; second, the bladder permeability barrier of the urothelium acts as an impenetrable barrier, and therefore the instilled drug cannot effectively penetrate to the target bladder tissue. 3 Thus, repeated urinary catheterization is required, which is uncomfortable for patients. 1 To overcome these disadvantages, urination prior to drug instillation, to empty the bladder cavity, and the regulation of fluid intake before and after drug instillation, to suppress urine production, were used as supportive strategies. However, these efforts did not result in a considerable increase in the drug residence time in the urinary bladder cavity. 4 Hydrogels are hydrophilic polymer networks that are able to retain plenty of water and maintain gel shape. [5] [6] [7] As many drugs, proteins, and cells can be easily incorporated into hydrogel formulations, hydrogels are of great interest in biomedical applications. Injectable hydrogels can form a drug reservoir in the target site via an in situ sol-gel transition after administration by simple injection. There are many mechanisms involved in the sol-gel phase transition, including pH-and temperature-induced transitions. 8, 9 Thermosensitive polymer hydrogels remain in a 'free-flowing' sol state, with low viscosity at low temperatures, and maintain an 'injectable' state. However, at elevated temperatures, such as body temperature, they rapidly undergo sol-gel transition and form a 'hard-to-flow' gel phase with high viscosity. 5 Therefore, after the polymer solution is easily injected into the target body site, it forms hydrogel at 37°C, which acts as the drug reservoir. Thermosensitive polymer solutions also have reversible gelling properties, with the ability to convert back into the polymer solution from the gel state at low temperatures. This characteristic enables the easy elimination of the hydrogel from the bladder cavity through simple washing with saline when administered into the urinary bladder. 1 The introduction of an injectable hydrogel via IDD can enhance the retention in the bladder cavity compared to that with a drug solution, even after periodic urine voiding. 10 Poloxamer copolymers are the group of block copolymers comprised of ethylene oxide (EO) and propylene oxide (PO) monomers. Since their introduction in the late 1950s, they have been used in various pharmaceutical applications. 11 The thermosensitive gelation of poloxamer copolymers is perfectly reversible and is characterized by a sol-gel transition temperature.
As presented P407 as an "inactive" material for various types of formulations, and it is generally considered to be nontoxic. 12, 17 Therefore, P407 offers a safe and appropriate thermosensitive gelling agent for intravesical delivery in hydrogel systems.
The intravesical administration of bacillus Calmette-Guerin (BCG) has been used in immunotherapy for superficial transitional cell bladder cancer. It was shown to reduce the number and frequency of recurrent tumors and to prevent disease progression. 18 BCG, the attenuated strain of the bovine tuberculous bacterium, consists of living bacilli, dead microorganisms, and subcellular debris; however, the immunological properties and antibiotic sensitivities of the parent strain are conserved. 19 When BCG contacts the bladder endothelium, it is endocytosed and induces inflammatory reactions with both CD4 and CD8 T-cells and macrophages. There is an increase in the production of cytokines, which also activate the lymphocytes. In clinical practice, as BCG solution is usually administered into the bladder cavity by urinary catheterization, the drugs are diluted by urine and eliminated regularly by periodic urination. Thus, to reduce urine production, water intake is restricted for 4 hours before instillation. It is recommended that patients suppress urination to allow sufficient absorption of BCG, but this is only of limited value. 20 Through the introduction of P407 hydrogel to enhance the retention of BCG, patient convenience is improved by the reduced need for re-peated catheterization.
In the present study, P407 hydrogels (P407Gels) were pre- 
MATERIALS AND METHODS

Materials
Poloxamer 407 (Kolliphor P 407) was kindly provided by (Seoul, Korea). Nude mice were purchased from Orient-Bio (Seongnam, Korea).
Preparation of P407Gels
Thermosensitive P407Gels were prepared by the 'cold' method. 21 To prepare FD-free P407gels as a control, 20-30 w/w% of P407 was added to a solution of PBS and stirred using magnetic stirrers overnight at 4°C until all the poloxamer granules were completely dissolved and a clear solution of P407 was obtained.
Separately, to prepare FD-loaded P407Gels (FD-P407Gels), 0.2 w/w% FD was dissolved in PBS solution, and then P407 was dissolved overnight at 4°C. All samples were prepared on a w/w basis and reported as a weight %. The prepared hydrogels were equilibrated at 4°C and 37°C and tilted to check for 'free-flowing' movement, which enabled the identification of the thermo-reversible sol-gel transition. 
Homogeneity of FD dispersion in FD-P407Gels
Images of the prepared FD-P407Gels were obtained by fluorescence microscopy (Motic, Beijing, China) to evaluate the homogeneity of the FD dispersion in the hydrogel matrix after the sol-gel transition. A 10-L sample of FD-P407Gel was placed on a microscope slide glass (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany), and observed by using a fluorescence microscope at ×40 magnification.
Measurement of gelation temperature and time
The G-Temp and G-Time of the hydrogel formulation were evaluated by using the test-tube inversion method. 
Measurement of gel strength of P407Gels
The strength of the developed hydrogel was evaluated in terms of G-Dur at body temperature, which was measured by a previously reported gravimetric test tube method. 24 A preweighed test tube (11-mm inner diameter) containing 0.5 mL of the hydrogel was equilibrated at 37°C, and the weight of the remaining hydrogel was calculated from the difference in the weight of the tube. PBS medium was equilibrated at 37°C, and 0.3 mL was carefully layered over the surface of the gel to avoid mixing. Tubes containing the gels and PBS medium were placed in an incubation chamber (SI-900R, Jeio Tech, Daejeon, Korea) maintained at 37°C. After predetermined time intervals (1 hour), the entire volume of PBS medium was removed and the weight of the test tube was measured. These processes were repeated until significant erosion was found. 
In vitro bladder simulation study
To mimic the human urinary bladder, an in vitro bladder simulation model was established from slight modifications of an earlier report. 26 Briefly, 12 mL of FD-P407Gel and FD-solution was injected via a pipette into a preweighed empty 250 mL round-bottom flask kept at 37°C. The weight of the flask plus the gel was measured. Then, PBS medium equilibrated at 37°C was added to the flask through the flask wall at a rate of 2 mL/min by using a peristaltic pump (BT100-2J, Longer
Precision Pump Co. Ltd., Hebei, China). After peristalsis for 2 hours, the entire volume of PBS medium was poured out.
The weight of the flask, in which the partially eroded gel remained, was measured to evaluate the retention behavior in the simulation model. Fresh PBS medium was pumped in again at the same rate and the above process was repeated 4 times.
Simultaneously, to evaluate the release of FD from the hydrogel, at predetermined time points, 0.5-mL PBS medium was sampled and an equal volume of fresh PBS was replaced. Each formulation was subjected to the test in triplicate under equivalent conditions. The amount of FD was quantified by HPLC. 
In vivo intravesical retention study
The retentive ability of FD-P407Gel and FD solution in the 
Statistical analysis
All data are expressed as the mean±standard deviation.
Significant differences were determined by using Student t-test with the level of significance set at p＜0.05. 
RESULTS
Preparation of
Characterization of gel-forming capacities
To evaluate the gel-forming capacities and select the appropriate concentration of P407, G-Temp and G-Time were measured by a test tube-inversion method, and G-Dur was measured by a gravimetric method. As shown in Table 1 
Retention of FD-P407Gels in the bladder simulation model
The in vitro experimental set-up for the bladder simulation model is illustrated in Fig. 2A . The round-bottom flask and PBS medium were placed in a water bath at 37°C. The peri- staltic pump was used to continuously infuse PBS medium to the flask at the rate of 2 mL/min. The infusion hose was stuck closely to the flask wall to allow the medium flow through it.
The process for periodic filling and emptying consisted of 4 repeated cycles, as depicted in Fig. 2B 
In vivo intra-vesical retention of FD-P407Gels
The retention behavior of FD-P407Gel was investigated by fluorescence imaging after intra-vesical instillation in the blad- 
DISCUSSION
We developed a thermosensitive hydrogel formulation for enhanced retention in the bladder. This formulation resulted in the sustained release of drug as an intravesical retentive drug reservoir. P407 is a biocompatible polymer that is widely used in pharmaceutical and medical applications because of its low toxicity. Moreover, P407 formulations have simple preparations and requires no organic solvents. For these reasons, P407 was selected for the preparation of the thermosensitive hydrogels.
FD is a fluorescent molecule with excitation and emission wavelengths of approximately 495 and 520 nm, respectively.
It can be easily solubilized in a hydrogel, with hydrophilicity similar to that of BCG; furthermore, BCG can be labelled with FD by using a simple incubation procedure. 28, 29 Thus, throughout this experiment, FD was used as a fluorescent probe because of its hydrophilicity and ability to label BCG.
Three main parameters were evaluated to ensure rapid gel formation and long-term retention in vivo. First, the G-Temp was the minimum temperature at which the thermosensitive hydrogel forms. To enable the phase transition into a gel in the bladder cavity after instillation, G-temp should be lower than body temperature (37°C). Simultaneously, it should not be below room temperature, to avoid a gelation that would complicate instillation. As all the G-Temp of all preparations (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) w/w%) were below body temperature, they were expected to undergo gelation after intra-vesical instillation. P407Gel with 20 w/w% was thought to be adequate, because the G-Temp was slightly higher than room temperature. Second, the G-Time is After accounting for all these parameters, 20 w/w% P407Gel was selected for further experiments.
We established an in vitro bladder simulation model for the evaluation of the intravesical formulations, which represented a close approximation of human bladder conditions. The round-bottom flask was used to mimic the round shape of the bladder. The PBS medium was chosen as the simulated urine, with the peristaltic pump used to simulate the urine production in the bladder (2 mL/min). 26 After the medium was infused for 2 hours, it was poured out to mimic the urine voiding. This which showed 50% retention after 6 hours (3 cycles). This discrepancy might be attributable to the differences in the volume of the hydrogel and the medium. In the case of the in vitro study, 12 mL of hydrogel was subjected to 240 mL of release medium in total for every cycle (2 hours). However, in the in vivo mouse model, 50-L hydrogel was instilled into the bladder cavity, as the maximum capacity of the bladder of nude mice is limited to approximately 100 L, following which urination is stimulated. 30 Moreover, the free movement of the mouse could affect the in vivo residence time compared with the in vitro model, which had no stirring process. Nevertheless, it was clear that FD-P407Gel showed extended retention in mouse bladder compared with the FD-solution, even after periodic urination.
CONCLUSIONS
A thermo-sensitive hydrogel system, P407Gels, was successfully developed for extended IDD. The system could be instilled by urinary catheterization without obstruction, and underwent thermo-sensitive gelation to yield enhanced retention.
We also established a novel bladder simulation model to mimic the human bladder environment, in which a periodic fillingemptying process over 2 hours was repeated for 4 cycles to evaluate the retention capability. The FD release from P407Gels and the erosion of the gel, both of which followed zero-order kinetics, demonstrated a proportional relationship. Finally, the in vivo study of intravesical instillation proved the excellence of P407Gels in terms of their retention performance in the bladder of nude mice. Thus, we conclude that P407Gels represent a promising system of extended drug delivery for the treatment of urinary bladder diseases.
